Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial
Authors:
- 30 March 2023
- journal article
- research article
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 7 (7) , 471-478
Abstract
No abstract availableKeywords
Funding Information
- Solving Kids' Cancer
- Duke University
- National Institutes of Health (K99CA263021, R01 NS108773)
- Andrew McDonough B+ Foundation
- Musella Foundation For Brain Tumor Research and Information
This publication has 18 references indexed in Scilit:
- Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant GliomasArchives of Pathology & Laboratory Medicine, 2017
- Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine GliomaCancer Cell, 2017
- Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLsScience Translational Medicine, 2017
- Pathogenic Events in a Nonhuman Primate Model of Oral Poliovirus Infection Leading to Paralytic PoliomyelitisJournal of Virology, 2017
- Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 studyNeuro-Oncology, 2016
- Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patientsNature, 2015
- Analysis of a simulation algorithm for direct brain drug deliveryNeuroImage, 2012
- Convection-enhanced delivery of therapeutics for brain disease, and its optimizationNeurosurgical Focus, 2006
- Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumorsNature Medicine, 1997
- Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants.Proceedings of the National Academy of Sciences, 1996